China’s BeBetter Medicine and PharmaEngine of Taiwan Form Cancer JV
Guangzhou BeBetter Medicine Technology has signed a collaborative research agreement with  Taiwan 's PharmaEngine to develop new chemical entities that address predefined oncology targets. BeBetter will own  China  rights to any discoveries, while PharmaEngine will be able to market the products in the rest of the world. BeBetter will undertake discovery of optimized NCEs for IND-enabling studies. PharmaEngine will be responsible for their development and commercialization. More details.... Stock Symbol: (TWO: 4162) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here